Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281076> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4379281076 endingPage "e21573" @default.
- W4379281076 startingPage "e21573" @default.
- W4379281076 abstract "e21573 Background: PD-1 inhibitors improve outcomes in resected stage II-IV melanoma. However, recurrence patterns and prognostic factors are less known. Methods: We conducted a retrospective study in resected stage II-IV melanoma patients (p) treated with adjuvant PD-1 inhibitors (clinical practice or clinical trials) from 5 centers. Demographic, disease characteristics, adjuvant therapy, recurrence, treatment at relapse and outcome were recorded. Descriptive assessment for recurrence patterns and analysis for prognostic factors were performed. Results: From June 2017 to June 2022, 181 p were included. Median age was 59 years [22-81], 57% were male, 85% had cutaneous melanoma, 28% had BRAF V600E mutation. 9 p (5%) presented stage II, 147 (81%) stage III and 25 (14%) stage IV. Ulceration was present in 59% p, mitotic rate >1/mm 2 in 84%, Breslow index >3 mm in 65% and elevated LDH in 51%. 81% p received PD-1 inhibitors alone and 19% in combination with other immunotherapies. 52% of p completed treatment, 12% discontinued due to toxicity and 26% due to relapse. 13% of p presented grade 3-4 adverse events and there was a grade 5 myocarditis. With a median follow-up of 18,1 months, 68 (37%) p recurred (Table). Median relapse free survival (RFS) was 48,8 months (95% CI 31,1-66,4). Recurrence was significantly associated with a higher stage, mitotic rate, LDH level and Breslow index, BRAF V600E mutation, non-cutaneous melanoma and delayed initiation of adjuvant immunotherapy in univariate analysis (p<0,05). Stage, non-cutaneous melanoma and initiation of immunotherapy >3 months (16% p) were associated with higher recurrence in multivariate analysis (<0,05). Locoregional recurrence was treated in 23 p with surgery (14p), surgery + RT (7p) or RT alone (2). Systemic recurrence was treated in 50 p: all BRAF mutant p received targeted therapy (24p, 43%) with a disease control rate (DCR) of 91% and a median progression free survival (PFS) of 56 months (95% CI 24,1-NR); BRAF wild type p (26p, 47%) were treated with anti-PD-1 alone (9p) or in combination (7p), anti-CTLA-4 (2p), chemotherapy (1p) or best supportive care (7p), with DCR of 33% and a median PFS of 8 months (95% CI 6,9-10,8). Conclusions: We observed a 37% relapse rate and systemic recurrence were more frequent than locoregional recurrence. Treatment at relapse with targeted therapy in BRAF mutant p achieved higher DCR and PFS than immunotherapy in BRAF wild type p; with better outcomes than previously reported.[Table: see text]" @default.
- W4379281076 created "2023-06-05" @default.
- W4379281076 creator A5002854538 @default.
- W4379281076 creator A5008993020 @default.
- W4379281076 creator A5055523372 @default.
- W4379281076 creator A5058642751 @default.
- W4379281076 creator A5058998750 @default.
- W4379281076 creator A5059355812 @default.
- W4379281076 creator A5064234791 @default.
- W4379281076 creator A5064483789 @default.
- W4379281076 creator A5073532733 @default.
- W4379281076 creator A5086809596 @default.
- W4379281076 creator A5090317819 @default.
- W4379281076 creator A5092083231 @default.
- W4379281076 date "2023-06-01" @default.
- W4379281076 modified "2023-10-18" @default.
- W4379281076 title "Multicenter analysis of melanoma recurrence pattern and management after adjuvant immunotherapy." @default.
- W4379281076 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e21573" @default.
- W4379281076 hasPublicationYear "2023" @default.
- W4379281076 type Work @default.
- W4379281076 citedByCount "0" @default.
- W4379281076 crossrefType "journal-article" @default.
- W4379281076 hasAuthorship W4379281076A5002854538 @default.
- W4379281076 hasAuthorship W4379281076A5008993020 @default.
- W4379281076 hasAuthorship W4379281076A5055523372 @default.
- W4379281076 hasAuthorship W4379281076A5058642751 @default.
- W4379281076 hasAuthorship W4379281076A5058998750 @default.
- W4379281076 hasAuthorship W4379281076A5059355812 @default.
- W4379281076 hasAuthorship W4379281076A5064234791 @default.
- W4379281076 hasAuthorship W4379281076A5064483789 @default.
- W4379281076 hasAuthorship W4379281076A5073532733 @default.
- W4379281076 hasAuthorship W4379281076A5086809596 @default.
- W4379281076 hasAuthorship W4379281076A5090317819 @default.
- W4379281076 hasAuthorship W4379281076A5092083231 @default.
- W4379281076 hasConcept C121608353 @default.
- W4379281076 hasConcept C126322002 @default.
- W4379281076 hasConcept C141071460 @default.
- W4379281076 hasConcept C143998085 @default.
- W4379281076 hasConcept C144301174 @default.
- W4379281076 hasConcept C146357865 @default.
- W4379281076 hasConcept C151730666 @default.
- W4379281076 hasConcept C2777658100 @default.
- W4379281076 hasConcept C2777701055 @default.
- W4379281076 hasConcept C2777863537 @default.
- W4379281076 hasConcept C2777982462 @default.
- W4379281076 hasConcept C2780212769 @default.
- W4379281076 hasConcept C2908643394 @default.
- W4379281076 hasConcept C38180746 @default.
- W4379281076 hasConcept C502942594 @default.
- W4379281076 hasConcept C530470458 @default.
- W4379281076 hasConcept C71924100 @default.
- W4379281076 hasConcept C86803240 @default.
- W4379281076 hasConcept C90924648 @default.
- W4379281076 hasConceptScore W4379281076C121608353 @default.
- W4379281076 hasConceptScore W4379281076C126322002 @default.
- W4379281076 hasConceptScore W4379281076C141071460 @default.
- W4379281076 hasConceptScore W4379281076C143998085 @default.
- W4379281076 hasConceptScore W4379281076C144301174 @default.
- W4379281076 hasConceptScore W4379281076C146357865 @default.
- W4379281076 hasConceptScore W4379281076C151730666 @default.
- W4379281076 hasConceptScore W4379281076C2777658100 @default.
- W4379281076 hasConceptScore W4379281076C2777701055 @default.
- W4379281076 hasConceptScore W4379281076C2777863537 @default.
- W4379281076 hasConceptScore W4379281076C2777982462 @default.
- W4379281076 hasConceptScore W4379281076C2780212769 @default.
- W4379281076 hasConceptScore W4379281076C2908643394 @default.
- W4379281076 hasConceptScore W4379281076C38180746 @default.
- W4379281076 hasConceptScore W4379281076C502942594 @default.
- W4379281076 hasConceptScore W4379281076C530470458 @default.
- W4379281076 hasConceptScore W4379281076C71924100 @default.
- W4379281076 hasConceptScore W4379281076C86803240 @default.
- W4379281076 hasConceptScore W4379281076C90924648 @default.
- W4379281076 hasIssue "16_suppl" @default.
- W4379281076 hasLocation W43792810761 @default.
- W4379281076 hasOpenAccess W4379281076 @default.
- W4379281076 hasPrimaryLocation W43792810761 @default.
- W4379281076 hasRelatedWork W1911828475 @default.
- W4379281076 hasRelatedWork W2039911714 @default.
- W4379281076 hasRelatedWork W2062616868 @default.
- W4379281076 hasRelatedWork W2167896894 @default.
- W4379281076 hasRelatedWork W2419557209 @default.
- W4379281076 hasRelatedWork W2462127705 @default.
- W4379281076 hasRelatedWork W3016866407 @default.
- W4379281076 hasRelatedWork W3095465973 @default.
- W4379281076 hasRelatedWork W3115204782 @default.
- W4379281076 hasRelatedWork W3176844910 @default.
- W4379281076 hasVolume "41" @default.
- W4379281076 isParatext "false" @default.
- W4379281076 isRetracted "false" @default.
- W4379281076 workType "article" @default.